T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data is available on T-DM1 efficacy after dual anti-HER2 blockade with pertuzumab and trastuzumab plus a taxane, which represents the current first-line standard of care. The present study is a retrospective/prospective evaluation of the efficacy and activity of second-line T-DM1 after front-line pertuzumab-based therapy.

T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study

Conte, Benedetta;Poggio, Francesca;Blondeaux, Eva;Dellepiane, Chiara;MOLINELLI, CHIARA;Boccardo, Francesco;Lambertini, Matteo;Del Mastro, Lucia
2019-01-01

Abstract

T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data is available on T-DM1 efficacy after dual anti-HER2 blockade with pertuzumab and trastuzumab plus a taxane, which represents the current first-line standard of care. The present study is a retrospective/prospective evaluation of the efficacy and activity of second-line T-DM1 after front-line pertuzumab-based therapy.
File in questo prodotto:
File Dimensione Formato  
tdm1-s2.0-S1526820919306718-main.pdf

accesso chiuso

Tipologia: Documento in versione editoriale
Dimensione 585 kB
Formato Adobe PDF
585 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/986330
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 1
social impact